When a patient needs lung cancer surgery, they have many decisions to make. The most important decision is the type of surgery that will be done on them. There are two types of surgeries: resection and lobectomy. A resection is when part of their lung is taken out so it can be examined for any remaining cancer cells. A lobectomy is when their entire lobe or lobe-section containing the tumor(s) is taken out, which means less healthy tissue will need to be removed during surgery because it’s not needed for breathing purposes anymore.
The choice between these two options depends on how much time has passed since the diagnosis was made, how large the tumor or tumors are in relation to other nearby structures in the lungs, and the patient’s age and general health.
Sometimes it isn’t clear which type of surgery would be best for the patient, so surgeons will try to determine if more than one lobectomy is necessary, or if they can remove all of the tumors through a single lobectomy first before moving on to the second. Other times, lobectomies are necessary because the tumors are too numerous and/or large to be removed through a resection, and this decision should only be made once all other options have been exhausted.
Lung cancer is the leading cause of cancer death in both men and women. It is estimated that there are more than 225,000 new cases diagnosed each year, with only about 15% of them living for at least one year after diagnosis. Lung cancer surgery can be a life-saving procedure, but unfortunately this type of surgery does not work on every patient because it depends on many factors such as age and general health.
Lung Cancer Surgery Market research report provides an all-encompassing study of the global lung cancer market based on various parameters like types (lobectomy vs resection), regional outlook (APAC vs Europe), competitive landscape (market share by key players) etc. The report also covers the major drivers, restraints, and opportunities impacting the global lung cancer market currently.
Lung Cancer Market – Drivers and Challenges
Some of the factors driving the growth of lung cancer surgery are increasing incidences of smoking-related cancers, rising geriatric population, availability of technologically advanced healthcare infrastructure across Europe and North America among others. However, high cost associated with a lung cancer surgery and reimbursement issues are some of the factors responsible for restraining the growth of this market.
Lung Cancer Market – Segmentation
The global lung cancer (lung neoplasms) market has been broadly categorized into three types: oat cell, non-small cell, and small cell carcinoma. The oat cell type is further sub-classified into two types, which are squamous cell carcinoma and large cell carcinoma.
Lung Cancer Market – Regional Outlook
The global lung cancer surgery market can be divided into five regions: North America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA), and Latin America. The North American region is expected to account for the highest market share in 2017, whereas Asia Pacific is expected to register the highest growth rate by 2024.
Lung Cancer Market – Competitive Landscape
The global lung cancer surgery market is characterized by a high degree of competition across various geographies with an increasing number of M&A’s and tie-ups between existing players and emerging start-ups. Some of the key players in this market are Nordion, Inc., Novadaq Technologies Inc., Cook Medical Incorporated, Stryker Corporation , and Olympus Corporation among others.